While the broader sector struggled, specific corporate developments offered pockets of activity. Austin-based 4E Therapeutics confirmed its acquisition by Eli Lilly. The neuroscience firm specializes in developing chronic pain treatments, focusing on compounds designed to provide relief without the central nervous system side effects common in existing therapies.
In section Market Quotes
Healthcare Equities Slip as Rate Concerns Weigh on Markets
Persistent fears that U.S. borrowing costs will stay elevated until inflation cools to the Federal Reserve’s 2% target triggered a broad selloff across the healthcare sector today. Investors retreated from medical equities, reflecting wider market anxiety over the duration of the current restrictive interest rate environment.
Separately, market sentiment toward UnitedHealth saw a boost from analysts at Leerink Partners. The firm raised its price target for the company to $462 from $400, pointing to improved margin forecasts for the Optum Health unit. This division remains a cornerstone of the company’s portfolio, currently providing medical care to millions of patients nationwide.
Comments (0)
No comments yet. Be the first!